---
title: "MEREO BIOPHARMA GROUP PLC — Ownership Dossier"
canonical: https://whiteintel.dev/entity/fb91e7f2-22a3-5689-8d38-0ec0e1379d9e
json: https://whiteintel.dev/api/public/dossier/fb91e7f2-22a3-5689-8d38-0ec0e1379d9e
identifier: oo:GB-COH-09481161
jurisdiction: GB
risk: Low
source: WhiteIntel corporate-ownership graph
---

# MEREO BIOPHARMA GROUP PLC

**Type:** Company  
**Jurisdiction:** [GB](https://whiteintel.dev/jurisdictions/gb)  
**Identifier:** `oo:GB-COH-09481161`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/fb91e7f2-22a3-5689-8d38-0ec0e1379d9e  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/fb91e7f2-22a3-5689-8d38-0ec0e1379d9e  

## Cross-source identity

The same real-world entity, resolved across sources:

- **MEREO BIOPHARMA GROUP PLC** — GLEIF · `lei:213800U8JQHIJOS5AS09` — https://whiteintel.dev/entity/05747226-f0a2-5542-b052-a1244f6f4ac2

## Ownership & control

### Owners / controllers

- **INVESCO ASSET MANAGEMENT LIMITED** (beneficial owner) — 50% — https://whiteintel.dev/entity/2d45a4e1-f204-59ed-9f12-d40d0aff0c78
- **WOODFORD INVESTMENT MANAGEMENT LIMITED** (beneficial owner) — 50% — https://whiteintel.dev/entity/882d6b4a-5024-51d8-bcdc-69bb110b574f
- **INVESCO ASSET MANAGEMENT LIMITED** (beneficial owner) — 37.5% — https://whiteintel.dev/entity/2d45a4e1-f204-59ed-9f12-d40d0aff0c78
- **WOODFORD INVESTMENT MANAGEMENT LIMITED** (beneficial owner) — 37.5% — https://whiteintel.dev/entity/882d6b4a-5024-51d8-bcdc-69bb110b574f

### Holdings / subsidiaries

- **MEREO BIOPHARMA 2 LIMITED** (beneficial owner) — 100% — https://whiteintel.dev/entity/3c0e4155-0ac8-543b-9746-c4392db1f5bb
- **MEREO BIOPHARMA 3 LIMITED** (beneficial owner) — 100% — https://whiteintel.dev/entity/153129f7-2dca-51b6-8eb3-2e824386b848
- **MEREO BIOPHARMA 4 LIMITED** (beneficial owner) — 100% — https://whiteintel.dev/entity/fb12de5b-2916-5cdb-b2b1-acf4a4d0a769
- **MEREO BIOPHARMA 1 LIMITED** (beneficial owner) — 100% — https://whiteintel.dev/entity/b4756e04-f883-5d02-ad76-bccf1927803b
- **MEREO BIOPHARMA 2 LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/3c0e4155-0ac8-543b-9746-c4392db1f5bb
- **MEREO BIOPHARMA 3 LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/153129f7-2dca-51b6-8eb3-2e824386b848
- **MEREO BIOPHARMA 4 LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/fb12de5b-2916-5cdb-b2b1-acf4a4d0a769
- **MEREO BIOPHARMA 1 LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/b4756e04-f883-5d02-ad76-bccf1927803b

### UBO chain (walk to the ultimate owner)

A **11-step** ownership/control chain to the ultimate beneficial owner is resolved for this entity. The full cited chain unlocks with a paid API key or a one-off dossier — https://whiteintel.dev/pricing.

## Company profile (live · UK Companies House)

- **Company number:** `09481161`
- **Status:** active
- **Type:** plc
- **Incorporated:** 2015-03-10
- **Registered office:** 4th Floor, One, Cavendish Place, London, W1G 0QF, England
- **SIC:** 72110

### Officers

- SERMON, Charles Edward — secretary · appointed 2023-11-09
- BENDER, Jeremy, Dr — director · American · appointed 2020-10-01
- EKBLOM, Anders — director · Swedish · appointed 2015-04-21
- JACQUET, Pierre, Dr — director · Belgian · appointed 2021-09-20
- PAKIANATHAN, Deepika, Dr — director · American · appointed 2019-04-23
- ROBERTS, Justin — director · American · appointed 2022-11-10
- SCOTS-KNIGHT, Denise Vera, Dr — director · British · appointed 2015-03-10
- SHAMES, Daniel, Dr — director · American · appointed 2022-11-10
- WYZGA, Michael — director · American · appointed 2019-04-23
- YOSKOWITZ, Marc — director · American · appointed 2022-11-10
- COSTELLO, Simon James — secretary · appointed 2023-03-31 · resigned 2023-11-08
- SERMON, Charles Edward — secretary · appointed 2015-05-19 · resigned 2023-03-31
- ARMSTRONG, Frank Murdoch — director · British · appointed 2015-04-21 · resigned 2019-02-08
- BAINS, Peter James Jonathan — director · British · appointed 2015-04-21 · resigned 2021-09-20
- BLACKBURN, Paul — director · British · appointed 2015-10-06 · resigned 2020-10-01
- BUNGAY, Richard Edward — director · British · appointed 2016-06-09 · resigned 2016-11-01
- FELLNER, Peter John, Dr — director · British · appointed 2015-07-29 · resigned 2022-11-10
- HYLAND, Anne Philomena — director · Irish · appointed 2022-03-01 · resigned 2022-11-10
- JENKINS, Annalisa, Dr — director · British · appointed 2022-11-10 · resigned 2026-05-14
- JONES, Richard Crispin — director · British · appointed 2017-01-30 · resigned 2020-06-29

### Beneficial owners (Persons with Significant Control)

- [Woodford Investment Management Limited](https://whiteintel.dev/entity/882d6b4a-5024-51d8-bcdc-69bb110b574f) — 25–50% shares · corporate PSC · England — ceased 2019-10-15
- [Invesco Asset Management Limited](https://whiteintel.dev/entity/2d45a4e1-f204-59ed-9f12-d40d0aff0c78) — 25–50% shares · corporate PSC · England — ceased 2019-04-23

## Provenance

- OpenOwnership — https://find-and-update.company-information.service.gov.uk/company/09481161
- companies_house_bulk — https://find-and-update.company-information.service.gov.uk/company/09481161

## Get the full, resolved dossier (agent-callable)

The above is the free teaser. The resolved **multi-hop UBO chain**, ownership **%**, full **financial history**, itemised **assets** and the hop-by-hop **exposure path** are the paid depth — callable as tools from your agent:

```bash
npx -y @whiteintel/mcp-server   # then: get_dossier · trace_ownership_path · check_offshore_exposure
```

Or unlock a one-off cited dossier for **MEREO BIOPHARMA GROUP PLC** — https://whiteintel.dev/entity/fb91e7f2-22a3-5689-8d38-0ec0e1379d9e · pricing https://whiteintel.dev/pricing.

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **MEREO BIOPHARMA GROUP PLC**. Human view: https://whiteintel.dev/entity/fb91e7f2-22a3-5689-8d38-0ec0e1379d9e · Structured JSON: https://whiteintel.dev/api/public/dossier/fb91e7f2-22a3-5689-8d38-0ec0e1379d9e._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._